Skip to main content
main-content

Glucagon-like peptide-1 (GLP-1) receptor agonists

Patient case study

Cardiovascular risk reduction in type 2 diabetes

Heart and stethoscope

Pharmacological management of comorbid cardiovascular risk and type 2 diabetes is undergoing a paradigm shift. General practitioner Kevin Fernando puts recommendations from the ADA/EASD into practice in this case study [read more].

Get more on: Cardiovascular disease | SGLT2 inhibitors | GLP-1 receptor agonists

medwireNews editor's pick

Possible bile duct cancer risk with incretin-based medications

Mixed pills

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

Expert opinion editorial

What have I learned from cardiovascular outcome trials?

Medication arranged in a heart shape

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future [read more]

Get more on: Cardiovascular disease | Type 2 diabetes | Expert opinion

medwireNews editor’s pick

Promising phase II data for dual GIP and GLP-1 receptor agonist

Subcutaneous injection_arm

A compound that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 has dose-dependent effects on glucose levels and bodyweight in people with type 2 diabetes.

medwireNews editor's pick

Lixisenatide may lessen albuminuria progression in type 2 diabetes

Kidneys

Macroalbuminuric patients with type 2 diabetes and a recent acute coronary event who are treated with lixisenatide may experience a reduction in their urinary albumin-to-creatinine ratio, suggests an exploratory post-hoc analysis of the ELIXA trial.

medwireNews editor’s pick

Albiglutide reduces cardiovascular risk in patients with type 2 diabetes

Heart and ECG_Fotolia_287046_Subscription_XL

Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.

medwireNews editor's pick

Targeting pathophysiology from outset may slow progression to type 2 diabetes

Pills_two types

Upfront treatment with medications that target the underlying pathophysiology of prediabetes may slow patients’ progression to type 2 diabetes, report researchers.

medwireNews editor's pick

Semaglutide shows promise for weight management

Obesity

Findings from a dose-ranging phase II trial published in The Lancet suggest that semaglutide, in combination with lifestyle intervention, may aid weight loss in people with obesity who do not have diabetes.

Journal article

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Doctor holding defibrillator (symbolic image with model)

The authors assess the risk of hospitalization due to HF with the use of dipeptidyl peptidase-4 inhibitors compared to glucagon like peptide-1 receptor agonists [read more].
Dawwas GK, Smith SM, Park H. Cardiovasc Diabetol 2018; 17: 102. doi: 10.1186/s12933-018-0746-4

Get more on:  Diabetic complications | Medication | Type 2 diabetes

Journal article

A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes: Metabolic effects and markers associated with bodyweight loss

Woman measuring her waist (symbolic image with model)

This post hoc analysis investigated the metabolic effects and baseline associations with bodyweight loss on coadministration of dapagliflozin and exenatide once weekly among adults with obesity and without diabetes [read more].
Pereira MJ et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0449-6

Get more on:  Medication | Obesity | Type 2 diabetes

medwireNews

03-14-2019 | Hypoglycemia | News

Real-world hypoglycemia data support continued sulfonylurea role in type 2 diabetes

Hypoglycemia is common among people being treated for type 2 diabetes, particularly those using insulin or a sulfonylurea, but the risk for severe episodes is only elevated among insulin users, suggest results of a prospective UK study.

03-05-2019 | Semaglutide | News

SUSTAIN 9 supports semaglutide, SGLT2 inhibitor combination

Adding the glucagon-like peptide-1 analog semaglutide to an existing sodium-glucose cotransporter 2 inhibitor improves glycemic control and bodyweight in patients with poorly controlled type 2 diabetes, SUSTAIN 9 data show.

03-04-2019 | SGLT2 inhibitors | News

Meta-analysis confirms SGLT2 inhibitor heart failure, kidney disease benefits

Sodium-glucose cotransporter-2 inhibitors have a greater effect than glucagon-like peptide-1 receptor agonists on reducing hospitalization for heart failure and kidney disease progression in patients with type 2 diabetes, according to the findings of a systematic review and meta-analysis.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

11-03-2018 | Liraglutide (T2DM) | Article

Liraglutide and glycemic outcomes in the LEADER trial

Zinman B et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0524-z

09-14-2018 | Insulin glargine/Lixisenatide | Article

Bedtime-to-morning glucose difference and iGlarLixi in type 2 diabetes: Post hoc analysis of LixiLan-L

Zisman A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0507-0

09-05-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

08-31-2018 | GLP-1 agonists | Review | Article

Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes

Bahtiyar G, Pujals-Kury J, Sacerdote A. Curr Diab Rep 2018; 18: 92. doi: 10.1007/s11892-018-1043-z

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

image credits